An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.

Published in: Expert review of clinical immunology (2022)

Compared with other TPO-RAs used to treat ITP, avatrombopag offers practical oral dosing with a single pill strength, does not require long-term dietary restrictions, and has no warning for hepatotoxicity. It is frequently effective after use of other TPO-RAs in ITP. The primary downside with avatrombopag use at present is the lack of longer-term safety data in ITP that presently exists for romiplostim and eltrombopag.

Keyphrases

wild type
drug induced
electronic health record
big data
gestational age
combination therapy
data analysis
preterm birth